Tissue Regenix Group PLC Tissue Regenix signs US distribution agreements (3373V)
December 12 2013 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3373V
Tissue Regenix Group PLC
12 December 2013
Tissue Regenix Group plc
Tissue Regenix signs United States distribution agreements
YORK, 12 December 2013 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the regenerative medical devices
company, today announces that it has signed seven independent
regional sales distribution agreements in the United States. The
regional distributors' represent over 40 sales representatives that
will actively promote DermaPure(TM), Tissue Regenix's dCELL(R)
human dermis into acute care hospitals, Veteran Affairs (VA)
Hospitals and institutions as well as Long Term Acute Care
hospitals (LTACs) in the US.
With the aim of targeting all the states within the US, Tissue
Regenix intends to sign further distribution agreements to ensure
sales coverage exists in all US metropolitan areas by the end 2014.
DermaPure(TM) also remains on course for its commercial launch in
the US during the first three months of 2014.
The distribution agreements will now allow Tissue Regenix to
promote DermaPure(TM) in the following states: Alaska, Washington,
Oregon, Idaho, Utah, Montana, New Mexico, Arizona, Minnesota, North
Dakota, South Dakota, Wisconsin, Illinois, Texas, Pennsylvania, New
York, Maryland, New Jersey, Delaware, Massachusetts, Connecticut,
Rhode Island, Vermont, Maine and New Hampshire.
Tissue Regenix established its USA subsidiary 'Tissue Regenix
Wound Care Inc.' in November 2012, as part of its commercialisation
strategy for its dCELL(R) technology platform. In June this year
the operation signed a processing agreement with Community Tissue
Services (CTS), one of the largest tissue banks in North America.
Through the agreement with CTS, Tissue Regenix's dCELL(R)
technology is now being applied to produce DermaPure(TM),for use
with acute and chronic wounds.
6.5 million US patients are afflicted by chronic wounds
currently. The partnership with CTS and the new distribution groups
is allowing Tissue Regenix to target the existing $1.4bn market for
wound healing devices & equipment, which is anticipated to
reach $1.5bn by 2016.[1]
Tissue Regenix's DermaPure(TM) works by taking human donor skin
and removing the DNA and cells, using the patented dCELL(R) process
to leave a natural biological scaffold that can be placed in the
wound to aid natural healing by attracting the patient's own cells
to the wound area.
A recently completed trial in the UK by NHS Blood and Transplant
('NHSBT') with the University Hospital of South Manchester has
shown that patients who have had chronic wounds for an average of
41/2 years and who were treated with a single application of Tissue
Regenix' DermaPure(TM) have seen an 87% reduction in the size of
all wounds, while 60% of patients were completely healed, with
virtually no recurrences.
Greg Bila, President of Tissue Regenix Wound Care Inc. said: "We
are delighted to have signed these seven regional distribution
agreements, allowing us to dispense DermaPure(TM) to 25 states in
the US. These agreements allow us to launch our institutional sales
strategy, and we are working hard with the distributors to bring
the product to market. With a significant distribution footprint
now in place across the US, we remain steadily on course for the
North American commercial launch of DermaPure(TM) in 2014."
ENDS
For Further Information
Tissue Regenix Wound Care Inc: +1 210 347 8302
Greg Bila
Tissue Regenix Group plc: +44 19 0443 5176
Antony Odell
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Alistair Kellie
Andrew Adie
Andrew Jones
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
[1] 'Wounds, gauzes and biofilms combine for an ugly triad' JG
Thomas, L Corum, H Mantlagh (2012)
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRFMMMZRMFGFZM
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024